While it may have been initially developed for the early detection of Alzheimer’s disease or other cognitive impairments in patients, it appears that Cognetivity Neurosciences’ (CSE: CGN) flagship product, CognICA, is also beneficial in the area of medical research. The firm this morning revealed that its technology will be used by the Baylor College of Medicine under a new clinical study.
The study will see the College look to understand the impact genetic factors have on the risk of developing obsessive-compulsive disorder, specifically in Latin American persons. The study will see the use of Cognetivity’s tool to detect subtle changes in cognition of those impacted by OCD. The data generated from these changes will be used to assist in understanding if genetic variants are behind clinically significant symptoms, which will then assist in identifying treatment targets.
“Using Cognetivity’s powerful CognICATM platform and its ability to sensitively and repeatedly measure cognitive function, regardless of linguistic and cultural differences, gives researchers the precise tool they need to better understand how patients’ cognitive performance changes in various stages of OCD in a way that has up to now been impossible,” commented Dr Eric Storch, Chief Investigator at the Baylor College of Medicine.
Sponsored · Selkirk Copper Mines
The use of the tech in a clinical research setting follows the company securing a paid pilot program in Japan with an insurance giant back in July. Under that arrangement the firm will see Mitsui Sumitomo Primary Life and Mitsui Sumitomo Aioi Life trial the tool before potentially deploying it to its massive base of clients.
Cognetivity Neurosciences last traded at $0.30 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
